(-0.27%) 4 288.05 points
(-0.47%) 33 508 points
(0.14%) 13 219 points
(0.34%) $91.10
(-1.09%) $2.90
(-0.28%) $1 860.80
(-1.58%) $22.10
(1.40%) 919.50
(0.06%) 0.946
(0.09%) 10.70
(0.08%) 0.820
(0.00%) 96.48
@ NOK96.80
Issued: 28 Sep 2023 @ 06:45
Return: 4.55%
Previous signal: Sep 27 - 09:23
Previous signal:
Return: 20.25 %
Live Chart Being Loaded With Signals
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase...
Stats | |
---|---|
Today's Volume | 124 543 |
Average Volume | 46 256.00 |
Market Cap | 3.48B |
P/E | -18.47 |
ATR14 | NOK7.80 (7.65%) |
Volume Correlation
Ultimovacs ASA Correlation
10 Most Positive Correlations | |
---|---|
AUSS.OL | 0.945 |
IDEX.OL | 0.94 |
LSG.OL | 0.931 |
NBX.OL | 0.93 |
EFUEL.OL | 0.911 |
TEL.OL | 0.907 |
AFG.OL | 0.887 |
ELIMP.OL | 0.885 |
GOGL.OL | 0.866 |
ELK.OL | 0.866 |
10 Most Negative Correlations | |
---|---|
FROY.OL | -0.962 |
TRE.OL | -0.9 |
NORSE.OL | -0.899 |
SPOG.OL | -0.843 |
ECIT.OL | -0.839 |
BWLPG.OL | -0.825 |
KAHOT.OL | -0.819 |
IWS.OL | -0.816 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ultimovacs ASA Correlation - Currency/Commodity
Ultimovacs ASA Financials
Annual | 2022 |
Revenue: | NOK0 |
Gross Profit: | NOK0 (0.00 %) |
EPS: | NOK-4.29 |
Q1 | 2023 |
Revenue: | NOK0 |
Gross Profit: | NOK0 (0.00 %) |
EPS: | NOK-0.510 |
Q4 | 2022 |
Revenue: | NOK0 |
Gross Profit: | NOK0 (0.00 %) |
EPS: | NOK-1.560 |
Q3 | 2022 |
Revenue: | NOK0 |
Gross Profit: | NOK0 (0.00 %) |
EPS: | NOK-0.950 |
Ultimovacs ASA
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.